TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Journal:

Journal of Clinical Oncology

Published:

2026-01-29

DOI:

10.1200/jco-25-02075

Affiliations:

12

Authors:

18

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	2.500000	0.14
Yale Cancer Center, United States of America (USA)	2.000000	0.11
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	2.000000	0.11
University of Pennsylvania Health System (UPHS), United States of America (USA)	2.000000	0.11
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	2.000000	0.11
Harvard Medical School (HMS), United States of America (USA)	1.500000	0.08
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.06
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	1.000000	0.06
The University of Chicago (UChicago), United States of America (USA)	1.000000	0.06
Duke University Hospital, United States of America (USA)	1.000000	0.06
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.06
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.06

Interested in Oncology and Carcinogenesis?